Ask about this productRelated genes to: ADAM8 antibody
- Gene:
- ADAM8 NIH gene
- Name:
- ADAM metallopeptidase domain 8
- Previous symbol:
- -
- Synonyms:
- CD156, MS2, CD156a
- Chromosome:
- 10q26.3
- Locus Type:
- gene with protein product
- Date approved:
- 1996-11-13
- Date modifiied:
- 2015-08-24
Related products to: ADAM8 antibody
Related articles to: ADAM8 antibody
- In hepatocellular carcinoma (HCC), stromal and immune components shape invasion and metastasis. To identify the cellular states that drive extracellular matrix (ECM) remodeling, define their organization at the tumor margin, and evaluate their association with prognosis, we profiled stromal regions at the tumor margin using single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, and multiplex immunofluorescence. Across scRNA-seq profiles from 79 patients, we identified a hypoxia-associated population of tumor-associated macrophages with high ADAM8 expression and upregulated ECM remodeling programs. Spatial transcriptomics and histology placed these ADAM8⁺ macrophages in stromal regions with disorganized collagen. They were often in hypoxic zones around necrosis and adjacent to FAP⁺ fibroblasts. Ligand-receptor analysis predicted engagement of the collagen-CD44 axis between the two cell types. In vitro, hypoxia induced expression of ADAM8 in macrophages. ADAM8 knockdown reduced the induction of TNF-α, IL-6, and IL-1β and weakened the ability of macrophages to activate fibroblasts. In tissue microarrays, a higher fraction of ADAM8⁺ macrophages among CD68⁺ cells predicted shorter overall and recurrence-free survival. Consistently, in a murine HCC model, pharmacological inhibition of ADAM8 decreased FAP⁺ fibroblast abundance. Overall, the data show that ADAM8⁺ macrophages and FAP⁺ fibroblasts form a hypoxia-linked ECM remodeling niche at the tumor boundary. This stromal remodeling unit associates with poor prognosis and suggests testable targets for stroma-focused therapy for HCC. - Source: PubMed
Publication date: 2026/05/13
Jian QianLi YufengDuan WeiqiYang JiajinZheng ZhuomengXie QingyuYu JianfengSun BoDeng YoucaiHe LiuqinLiu Sulai - Vascular calcification (VC) is an inflammatory disease driven by aberrant cellular processes in which macrophages play an important role. The A disintegrin and metalloproteinase 8 (ADAM8) protein is an important regulatory factor in macrophages and contributes to the development of inflammatory diseases. However, the relationship between ADAM8 and VC remains unknown. Thus, this study aimed to investigate the role of macrophage ADAM8 in VC. - Source: PubMed
Dong RongJi ZhenjunWang MiTao ZaixiaoLi XinxinZhang RuiXu JunweiMa Genshan - : To determine which age of mice should be used to compare the effects of ADAM8 mutation on intervertebral disc (IVD) responses to injury. : IVDs of ADAM8 mutant () and wild type (WT) mice, aged 3, 10 and 18 months were injured. IVD tissues were harvested 1 week post injury for histological and molecular studies. : Histological scores increased with aging in intact IVDs, and there were no differences between and WT mice (n = 11-28; > 0.05). Safranin O-staining was less intense in 10-month than in 3-month-old mice, in both intact and injured IVDs (n = 3-15; < 0.05). , , and gene expression levels were higher in the injured tail IVDs of 3-month-old than WT mice (n = 18-30; < 0.05); the injury-related differences diminished with increasing age. : No histological differences were found between and WT mouse IVDs at 3, 10 or 18 months of age, in the intact or injured discs. The differences in inflammatory marker gene expression were detectable at age 3 months, but were less evident when the injury occurred at age 10 or 18 months. Therefore, to identify differences in injury responses between WT and mouse IVDs, 3-month-old mice are superior to older mice. - Source: PubMed
Publication date: 2026/04/20
Yao LutianWang HuanTian ZuozhenShofer Frances SQin LingZhang Yejia - Eosinophilic and neutrophilic inflammation, along with tissue remodeling, are key pathogenic features in chronic rhinosinusitis with nasal polyps (CRSwNP). While A Disintegrin and Metalloproteinase 8 (ADAM8) is implicated in inflammation and remodeling in various contexts, its specific role in CRSwNP remains unclear. - Source: PubMed
Publication date: 2026/04/22
He TingWang XiangdongZhang QinqinZhuang MengyanZhang YuanCheng MengyuanYu XiaoruLi YingJiao JianZhang LuoBachert Claus - Colorectal cancer (CRC) remains a major global health challenge, primarily due to late-stage diagnosis and high metastatic potential. Effective management requires novel diagnostic and prognostic strategies, with a growing focus on molecular biomarkers. A Disintegrin and Metalloproteinase (ADAM) proteins, characterized by unique proteolytic activity, play a fundamental role in tumorigenesis by regulating tumor growth, epithelial-mesenchymal transition (EMT), and metastasis. Based on recent investigations, among all ADAMs, ADAM8, ADAM9, ADAM12, ADAM15, and ADAM17 have been proved to play an important role in the CRC pathogenesis. Thus, this review underscores the potential of selected ADAM family members as promising candidates for biomarkers of CRC. Elevated ADAM8, ADAM9, ADAM12 and ADAM17 levels were observed in CRC tissues and correlated with more advanced tumor stage, while increased serum ADAM15 concentrations associated with the presence distant metastases. Moreover, ADAM9, ADAM12, ADAM15 and ADAM17 levels were associated with poorer survival, whereas ADAM8 overexpression was found to be independent prognostic factor for CRC patients' survival. In addition, the measurement of serum ADAM15 concentrations, especially in combination with well-established tumor marker-CEA improved the diagnosis of patients with this malignancy. In conclusion, selected ADAM are critical contributors to the development and progression of CRC, affecting tumor growth, EMT, and metastasis. ADAM8, ADAM9, ADAM12, ADAM15 and ADAM17 were identified as promising biomarkers for the assessment of CRC progression and proved to be prognostic indicators for patients' survival. Further validation through large prospective studies and standardized assays is necessary to establish their potential in clinical practice. - Source: PubMed
Publication date: 2026/04/01
Romanowicz AdriannaŁukaszewicz-Zając MartaMroczko Barbara